



CENIX BIOSCIENCE ANNOUNCES APPOINTMENT OF ZISI FOTEV AS NEW CHIEF BUSINESS OFFICER

Dresden, Germany – January 27, 2004 - Cenix BioScience GmbH, the premier provider of advanced RNAi research services, announced today that Zisi Fotev, Ph.D. has joined the company as Chief Business Officer. In this role he will have overall responsibility for the licensing and marketing of Cenix' s advanced RNAi research services, negotiating corporate partnerships and other strategic alliances.

"Zisi has more than 15 years of industry experience and an in-depth understanding of the pharmaceutical and biotechnology arena", said Christophe Echeverri, Ph.D., Chief Executive Officer and Chief Scientific Officer of Cenix BioScience. "With his outstanding track record of successful deal making, we look forward to further strengthening Cenix's market presence in the drug discovery market".

Dr. Fotev brings considerable scientific and business development experience to Cenix, having in the past served as Vice President of Business Development at atugen AG in Berlin and prior to that as Head of Licensing and Strategic Alliances at Merck KGaA Pharmaceuticals division. At atugen he was instrumental in establishing a strong market share for the target validation business and negotiating over 15 major deals with pharmaceutical companies from the USA, Europe and Japan.

Zisi Fotev holds a Bachelors of Science degree from the University of Western Australia and a Ph.D. from the University of Tuebingen in Germany.

About Cenix BioScience

Cenix BioScience GmbH is a pioneering leader in genome-based high throughput (HT) applications of RNA-mediated interference (RNAi) for the discovery and validation of new therapeutic drug targets. Founded in 1999 as the first biotechnology company specializing exclusively in HT-RNAi, Cenix has accumulated unparalleled depth and breadth of experience in this field, combining high content phenotypic analyses with proprietary genome-wide RNAi libraries for use in key experimental systems including human cells, Drosophila and C. elegans. Cenix is now making its unique expertise accessible to industry and academic researchers through fully customized research service offerings. For more information, please visit www.cenix-bioscience.com.

Contacts

Zisi Fotev, Ph.D.
Chief Business Officer
Tel. +49-351-210-2640
fotev@cenix-bioscience.com

Ellen Fuerst
Public Relations
Tel. +49-351-210-2511
fuerst@cenix-bioscience.com